Mesenchymal Stem Cells in Primary Sjögren’s Syndrome: Prospective and Challenges

Abstract EN

Primary Sjögren’s syndrome (pSS) is a chronic systemic inflammatory autoimmune disease characterized by lymphocytic infiltrates in exocrine glands.

Current approaches do not control harmful autoimmune attacks or prevent irreversible damage and have considerable side effects.

Mesenchymal stem cells (MSCs) have been effective in the treatment of several autoimmune diseases.

The objective of this review is to illustrate the potential therapeutic role of MSCs in pSS.

We summarize the recent advances in what is known about their immunomodulatory function and therapeutic applications in pSS.

MSC transfusion can suppress autoimmunity and restore salivary gland secretory function in mouse models and patients with pSS by inducing regulatory T cells, suppressing Th1, Th17, and T follicular helper cell responses.

In addition, MSCs can differentiate into salivary epithelial cells, presenting an option as a suitable alternative treatment.

We also discuss current bioengineering methods which improve functions of MSCs for pSS.

However, there remain many challenges to overcome before their wide clinical application.